Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial

Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial

Deadly cholesterol that doesn’t show up on routine tests is slashed by 94% with single dose of new drug

A new drug can potentially significantly reduce levels of lipoprotein(a), a type of undetected cholesterol that can spike the risk of heart disease.